A Phase 4 interventional study of Cetirizine and Loratadine in Allergic Rhinitis, Hay Fever and SAR, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-04-20.
Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Cetirizine · Rhinitis, Allergic, Seasonal.
Among the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal, this one has the largest enrollment, is the only one that started in 2001, is one of 6 in phase 4, and was the 10th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Cetirizine: first FDA approval 1995 (ZYRTEC HIVES). What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 683 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 117 across the 10 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Johnson & Johnson Consumer and Personal Products Worldwide, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.
Johnson & Johnson has 5 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.
This was a multi-center, randomized, double-blind, parallel-group, placebo-controlled, double dummy study of children with SAR conducted during the Spring tree and grass allergy season. Subjects qualified for randomization if the diary cards included (1) symptom scores of ≥2 for at least 2 of the following 4 rhinoconjunctivitis symptoms on 4 or more days: sneezing, runny nose, itchy eyes, and watery eyes; and (2) a total rhinoconjunctivitis (or Total Symptom Severity Complex [TSSC]) score of ≥5 on any 4 days. The TSSC score was expressed as the sum of the 4 individual symptoms scores recorded in the daily diary cards for the following symptoms: sneezing, runny nose, itchy eyes, and watery eyes.
Subjects were randomized to receive 1 of 3 treatments in a double-blind fashion using a 1:1:1 allocation ratio: cetirizine HCl syrup and placebo loratadine syrup; loratadine syrup and placebo cetirizine HCl syrup; or cetirizine placebo syrup and loratadine placebo syrup.
Number of Subjects (Planned and Analyzed): 1100 planned; 1536 screened; 683 randomized: 231 (33.8%) randomized to the cetirizine HCl treatment group, 221 (32.4%) to the loratadine treatment group, and 231 (33.8%) to the placebo treatment group.
Test Product and Reference Therapy: Subjects randomized to receive cetirizine HCl syrup also received placebo syrup; subjects randomized to receive loratadine syrup also received placebo syrup; and both placebo syrups were received by subjects randomized to receive placebo.
Duration of Double-Blind Treatment: 2 weeks.
Safety measures included the incidence and severity of treatment-emergent adverse events (AEs), vital signs, concomitant medications, and physical examination findings. Clinical laboratory evaluation was not required for this study.
Statistical Methods: All statistical tests related to treatment effect were 2-sided, and statistical significance was declared at the 0.05 probability level. Least squares means (LSMeans) were used to estimate treatment effect. Populations analyzed included the Full Analysis (intent-to-treat [ITT]) Set (FAS), Per-Protocol Set (PPS), Safety-Analyzable Set, and All-Screened Analysis Set. Demographic and baseline data for all subjects in the Safety-Analyzable Set were summarized and listed. The effects of treatment at the Overall and all other analysis Time Points were assessed using ANCOVA models. The main effects model contained terms for treatment and Investigator site, with baseline TSSC value as a covariate. The LSMeans and standard errors were based on the main effects model. Methods of analysis of secondary efficacy data included analysis of covariance (ANCOVA) models and Cochran-Mantel-Haenszel (CMH) row mean scores tests. Analysis of drug safety included the incidence of treatment-emergent AEs (TEAE), concomitant medications, vital signs, and physical examination findings for the Safety-Analyzable Set.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
This study's enrollment of 683 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.
First submitted before Johnson & Johnson Consumer and Personal Products Worldwide left Johnson & Johnson.
Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
Drug: Cetirizine
Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
Drug: Loratadine
Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
Other: Placebo
Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
Also known as: ZYRTEC
Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
Also known as: CLARITIN
Placebo syrup once daily before 10:00 AM for 2 weeks
Change from baseline to the Overall endpoint in the subject 24-hour reflective total symptom severity complex (TSSC) score
Time frame: 2 weeks
Change from baseline to the Overall endpoint in the subject 24-hour reflective TSSC, with and without stuffy nose score
Subject rated reflective TSSC on 5-point scale
Time frame: 2 weeks
Change from baseline to the Overall endpoint in the individual rhinoconjunctivitis symptoms (reflective and instantaneous)
Subject rated individual symptom severity on 5-point scale (reflective and instantaneous)
Time frame: 2 weeks
Investigator evaluation of rhinoconjunctivitis symptoms
Change from baseline to all secondary time points (Week 1 \[average of TSSC scores during Week 1 of double-blind treatment\], Week 2 \[average of TSSC scores during Week 2 of double-blind treatment\], and Endpoint \[last available post-baseline TSSC score\]) in subject 24-hour reflective TSSC.
Time frame: 2 weeks
Parent/legal guardian evaluation of subject's rhinoconjunctivitis symptoms
Change from baseline to all secondary time points (Week 1 \[average of TSSC scores during Week 1 of double-blind treatment\], Week 2 \[average of TSSC scores during Week 2 of double-blind treatment\], and Endpoint \[last available post-baseline TSSC score\]) in subject 24-hour reflective TSSC.
Time frame: 2 weeks
Investigator Global Evaluations of Efficacy at Visit 4/early termination
Investigator assess the therapeutic regimen's effect on 7-point scale
Time frame: 2 weeks
Subject/Parent/Legal Guardian Global Evaluations at Visit 4/early termination
Subject/Parent/Legal Guardian provided global evaluation of treatment on a 5-point scale
Time frame: 2 weeks
Parent/Legal Guardian Overall Personal Satisfaction Assessment at Visit 4/early termination
Parent/Legal Guardian provided appraisal of overall personal satisfaction with treatment on a 5-point scale
Time frame: 2 weeks
Parental Burden Questionnaire
At Visits 2, 3, and 4/early termination, the parent/legal guardian assessed the social and emotional impact of caring for a child with SAR on a 5-point scale
Time frame: 2 weeks
No study locations are listed for this record.
Plan to share: Yes
No publications or documents are linked to this record.
The record gives a start of Mar 2001, a primary completion of Jul 2001 and a completion of Jul 2001. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
Rhinitis, Allergic, Seasonal →
Johnson & Johnson Consumer and Personal Products Worldwide →